#,Qustion Type,Question
1,Basic/statistical,What is the MSK-IMPACT dataset about?
2,Basic/statistical,What does the 'Mutation Count' column represent?
3,Basic/statistical,What clinical attributes are there in the MSK CHORD study?
4,Basic/statistical,"What are the different types of 'Sample Type' in the MSK CHORD study, and how many samples (and what percentage) does each type represent?"
5,Basic/statistical,What is the median tumor-mutation-burden (TMB) score in lung adenocarcinoma samples with TP53 mutation?
6,Basic/statistical,"Which treatments does PrimeKG highlight for HER2-positive breast cancer, and why are they considered effective?"
7,Basic/statistical,What are the most common mutations in patients with Colon Adenocarcinoma?
8,Basic/statistical,"What kind of data in the MSK-CHORD study reflects MSI/MMR status, and how is it represented?"
9,Basic/statistical,What are the most frequently mutated genes in non-small cell lung cancer (NSCLC) samples?
10,Basic/statistical,How often do patients with breast cancer develop liver metastases?
11,Basic/statistical,Which mutations are most commonly found in Breast Invasive Ductal Carcinoma samples?
12,Basic/statistical,Are PIK3CA mutations more common in primary or metastatic breast tumors?
13,Basic/statistical,What are the most common metastatic sites for colorectal cancer?
14,Basic/statistical,What is the predominant biological sex of patients?
15,Basic/statistical,"What is the average highest reported Gleason score for patients diagnosed with prostate cancer, and how does it vary by stage?"
16,Basic/statistical,What is the range of tumor purity observed in metastatic breast cancer samples?
17,Basic/statistical,"How many ""Prissmm"" uniqe recrod types are int CCDE data?"
18,Basic/statistical,What is the average mutation count in patients?
19,Basic/statistical,Is there a difference in overall survival between smokers and non-smokers diagnosed with non-small cell lung cancer?
20,Basic/statistical,Do male or female patients with Large Cell Lung Carcinoma have a higher average number of mutations?
21,Basic/statistical,How frequently do we examine individuals with multiple primary tumors?
22,Basic/statistical,Do metastatic sites vary based on cancer type?
23,Basic/statistical,Is there a correlation between Gleason score and overall survival in prostate cancer patients?
24,Basic/statistical,Is there a correlation between smoking history and Pancreatic Cancer?
25,Basic/statistical,Is there a correlation between mutation count and fraction genome altered?
26,Basic/statistical,Is MYC copy number amplification in non-small cell lung cancer associated with overall survival?
27,Basic/statistical,Is CDKN2A copy number loss in pancreatic cancer associated with overall survival?
28,Basic/statistical,Is ATM mutation in the PanCancer cohort associated with overall survival?
29,Basic/statistical,Is KRAS mutation in the NSCLC cohort associated with overall survival?
30,Basic/statistical,Do patients with HER2-positive breast cancer have a better survival rate than HER2-negative patients?
31,Basic/statistical,How do TP53 and PIK3CA mutations affect treatment choices for endometrial cancer?
32,RAG/LLM,What are the treatment options for an 81-year-old woman with endometrial cancer and pelvic metastasis?
33,RAG/LLM,"What medical treatment would be appropriate for an 81-year-old Asian female diagnosed with endometrial cancer? The cancer stage is 1-3, with a biopsy from a pelvic metastasis showing TP53 (likely oncogenic), PIK3CA (oncogenic), and IKZF1/LATS1 mutations (unknown significance). The primary site is the uterus."
34,RAG/LLM,What medical treatment would be appropriate for an 81-year-old Asian female diagnosed with endometrial cancer?
35,RAG/LLM,"What treatment options are recommended for a 67-year-old Black male with lung cancer and liver metastasis, showing KRAS and STK11 mutations?"
36,RAG/LLM,"Which targeted therapies could be considered for a 74-year-old White male with bladder cancer, presenting with FGFR3 and TP53 mutations?"
37,Basic/statistical,Which genes tend to have pathogenic or likely pathogenic mutations for Breast cancer?
38,Basic/statistical,"If a tumor tests positive for a KRAS mutation, what therapies or targeted agents does PrimeKG suggest, and what evidence supports their use?"
39,Basic/statistical,"Which signaling pathways are most frequently implicated in advanced bladder cancer, and how do drugs in PrimeKG target these pathways?"
40,Basic/statistical,"What are the known resistance mechanisms against EGFR inhibitors in colon cancer, and does PrimeKG suggest any combination therapies to overcome them?"
41,Basic/statistical,"Are there any combination treatments that improve outcomes for melanoma patients with BRAF V600E mutations, based on PrimeKG data?"
42,Basic/statistical,How does PrimeKG link multi-gene testing results to possible treatment paths for triple-negative breast cancer
43,Basic/statistical,"If a tumor carries both BRCA1 and TP53 mutations, which recommended therapies does PrimeKG identify, and what is their mechanism of action?"
44,Basic/statistical,Is there any association between patients’ socioeconomic status and their cancer stage at diagnosis or survival outcomes?
45,Basic/statistical,What proportion of patients come from very low socioeconomic backgrounds according to the Yost Index?
46,Basic/statistical,"How is the Yost Index determined for each patient, and what does “Imputed, Median” mean in this context?"
47,Basic/statistical,What is the distribution of baseline ECOG performance status in prostate cancer patients cohort?
48,Basic/statistical,How many patients had an ECOG performance status of 2 or worse.
49,Basic/statistical,Does initial ECOG performance status correlate with overall survival in the MSK CHORD study?
50,Basic/statistical,"What does the value in the ECOG, 1st Reported column represent for each patient?"
51,Basic/statistical,What are the average and median BMI for patients with breast cancer in the MSK CHORD study?
52,Basic/statistical,What proportion of patients were overweight or obese at baseline?
53,Basic/statistical,How many patients were underweight at baseline?
54,Basic/statistical,What is the average BMI of breast cancer patients who have TP53 mutations?
55,Basic/statistical,Is there a correlation between the Yost Index and tumor mutation burden in the MSK CHORD study?
56,Basic/statistical,Do patients with metastatic disease (Stage 4) have a higher mutation burden than those with earlier stage cancers?
57,Basic/statistical,Does baseline performance status relate to mutation burden?
58,Timeline (2),Run a comparison between responders and non-responders to Irinotecan based on their PSA trends during the first month.
59,Timeline(2),Compare progression-free intervals for patients who received Leuprolide early vs. those who received it after other agents.
60,Timeline (2),How do response rates differ between patients treated with Topotecan who had prior treatment with Cyclophosphamide?
61,Timeline(2),Run a comparison of CEA levels between patients who remained on investigational drugs for >2 months and those who discontinued earlier.
62,Timeline(2),What differences exist between patients who progressed after Doxorubicin and those who remained stable for at least 3 months?
63,Timeline (3),Who are the most similar patients based on PSA trends and treatment timelines during the first 4 months?
64,Timeline (3),A 51-year-old woman with Non-Small Cell Lung Cancer and TP53 mutation completed Pemetrexed 2 months ago. CEA remains stable. Show 10 patients with similar treatment sequences and genomic profile to this current case.
65,Timeline(2),"Among prostate cancer patients who received either Degarelix or Leuprolide as hormone therapy, how do CEA levels typically evolve over time, and are there notable differences in the timing of CEA reduction between the two groups?"
66,Timeline (3),"Can you show examples of patients with Non-Small Cell Lung Cancer who progressed shortly after chemotherapy, and what outcomes were observed in similar cases?"
67,Timeline(1),How have patients with prior use of Degarelix and stable CEA historically responded to chemotherapy escalation?
68,Timeline,What is the typical PSA response in patients treated with Leuprolide following investigational therapy?
69,Timeline (1),Among women patients with Breast Cancer
,,"(Breast Invasive Ductal Carcinoma )who received LETROZOLE, how did CEA behave over time?"
70,Timeline(1),"For patients who showed lab stability during hormone therapy, what outcomes were seen after switching to radiation?"
71,Timeline(1),A 50-year-old man diagnosed with metastatic disease completed Irinotecan treatment in June 2024. What is the expected progression timeline if no further therapy is given based on similar patients?
72,Timeline(1),A 48-year-old man with diagnosed metastatic colorectal cancer has been on Irinotecan since March 2024. CEA levels started rising significantly in July. Can you find similar patients and list them?
73,Timeline (2),How do PSA trends differ between prostate cancer patients treated with Leuprolide before vs. after progression?
74,Timeline(1),What treatment outcomes have been seen in colorectal cancer patients who showed CEA elevation during the second month of Irinotecan therapy?
75,Timeline (2),Show examples of patients who started hormone therapy after a delay of more than one month following chemotherapy and how their progression timelines compare.
76,Timeline,"Among patients with TP53 mutations, how does the sequence of chemotherapy followed by investigational therapy impact progression-free survival?"
77,Timeline (3),"Which patients received a similar sequence of Fluorouracil → Oxaliplatin → Irinotecan, and how did they respond in terms of CEA levels and imaging?"
78,Timeline (4),Return all patients with an AR mutation in a prostate sample taken after receipt of leuprolide (prostate cancer).
79,Timeline (4),Return all patients who had a rising PSA after starting leuprolide and never had a decreasing PSA (prostate cancer).
80,Timeline (4),Return all patients who received radiation therapy before receiving docetaxel for non-small cell lung cancer (NSCLC).
81,Timeline (4),Return all patients who had an ECOG score of 2 or greater at the start of pembrolizumab treatment (pan-cancer).
82,Timeline (4),Return all patients who had a ≥20% decrease in BMI since diagnosis date or progression date (pan-cancer).
83,Timeline (4),"Return the distribution of BMI values for these patients (before and after), as well as the distribution of cancer antigen measurements (before and after) (pan-cancer)."
84,Timeline (4),"Find specific values/distribution of BMI values for these patients (before and after), as well as cancer antigen measurement distribution (before and after) (pan-cancer)."
85,Timeline (4),Return all patients with a continuously decreasing CEA level following treatment with fluorouracil and leucovorin (colorectal cancer).
86,Timeline (4),Return all patients who remained progression-free for at least 12 months following treatment with fluorouracil and leucovorin (colorectal cancer).
87,Timeline (4),"Return all patients with non-small cell lung cancer (NSCLC) who received targeted therapy with erlotinib, experienced a progression-free episode following treatment, and have had no documented tumor progression to date."
88,Timeline (4),Return all NSCLC patients with continuous ERLOTINIB treatment lasting over 9 months.
89,Timeline (4),Return all non-small cell lung cancer patients who received radiation therapy before starting ERLOTINIB.
90,Timeline (4),Return all NSCLC patients with no tumor progression for at least 6 months following any treatment.
91,Timeline (4),Return all patients with an AR mutation who received leuprolide (prostate cancer)
92,Timeline (4),Return all patients with EGFR mutation who received radiation therapy before receiving docetaxel for non-small cell lung cancer (NSCLC).
93,Timeline (4),Return all patients with a PIK3CA mutation and elevated CEA (colorectal cancer) for at least 6 months.
94,Timeline (4),Return all patients with an AR mutation and persistently rising PSA (prostate cancer) who received leuprolide treatment for more than 6 months.
95,Timeline (4),Return all patients with EGFR mutation who had no documented progression after erlotinib. (NSCLC)
96,RAG/LLM,"What are the next-line treatments for a 69-year-old Asian woman with breast cancer and a history of TAMOXIFEN, ANASTROZOLE hormone treatment showing PIK3CA and BRCA1 mutations?"
97,RAG/LLM,"What treatment strategy would you recommend for a 55 yar old female patient with Breast Invasive Ductal Carcinoma, high tumor purity (0.9), and PTEN mutation?"
98,RAG/LLM,"What treatments could be considered for a 65 years old male patient with Colorectal Cancer, Stable MSI score , and TMB in the 95th percentile?"
99,RAG/LLM,What targeted therapies are suitable for a 68-year-old male current smoker with squamous cell lung cancer and FGFR1 amplification?
100,RAG/LLM,"What treatments could be considered for a 65 years old male patient with Colorectal Cancer, Stable MSI score , and TMB in the 95th percentile?"
101,RAG/LLM,"What treatment strategy would be appropriate for a 62-year-old male patient with prostate cancer and previous ADT treatment, presenting with TP53 and RB1 mutations?"
,,
102,RAG/LLM,What treatment is appropriate for a 68-year-old woman with Stage III non-small cell lung cancer with KRAS and TP53 mutated genetic profile?
